Cargando…

Marked enhancement of lysosomal targeting and efficacy of ErbB2-targeted drug delivery by HSP90 inhibition

Targeted delivery of anticancer drugs to tumor cells using monoclonal antibodies against oncogenic cell surface receptors is an emerging therapeutic strategy. These strategies include drugs directly conjugated to monoclonal antibodies through chemical linkers (Antibody-Drug Conjugates, ADCs) or thos...

Descripción completa

Detalles Bibliográficos
Autores principales:	Raja, Srikumar M., Desale, Swapnil S., Mohapatra, Bhopal, Luan, Haitao, Soni, Kruti, Zhang, Jinjin, Storck, Matthew A., Feng, Dan, Bielecki, Timothy A., Band, Vimla, Cohen, Samuel M., Bronich, Tatiana K., Band, Hamid
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4891137/ https://www.ncbi.nlm.nih.gov/pubmed/26859680 http://dx.doi.org/10.18632/oncotarget.7231

Ejemplares similares

CHIP/STUB1 Ubiquitin Ligase Functions as a Negative Regulator of ErbB2 by Promoting Its Early Post-Biosynthesis Degradation
por: Luan, Haitao, et al.
Publicado: (2021)

Continuous requirement of ErbB2 kinase activity for loss of cell polarity and lumen formation in a novel ErbB2/Neu-driven murine cell line model of metastatic breast cancer
por: Ortega-Cava, Cesar F., et al.
Publicado: (2011)

Mechanisms of Trastuzumab resistance in ErbB2-driven breast cancer and newer opportunities to overcome therapy resistance
por: Bailey, Tameka A., et al.
Publicado: (2011)

A Comprehensive, Multi-Scale Dynamical Model of ErbB Receptor Signal Transduction in Human Mammary Epithelial Cells
por: Helikar, Tomáš, et al.
Publicado: (2013)

VAV1-Cre mediated hematopoietic deletion of CBL and CBL-B leads to JMML-like aggressive early-neonatal myeloproliferative disease
por: An, Wei, et al.
Publicado: (2016)

Proteasome Inhibitors Suppress ErbB Family Expression through HSP90-Mediated Lysosomal Degradation
por: Huynh, Thanh Kieu, et al.
Publicado: (2019)

A novel CBL-B(flox/flox) mouse model allows tissue-selective fully conditional CBL/CBL-B double-knockout: CD4-Cre mediated CBL/CBL-B deletion occurs in both T-cells and hematopoietic stem cells
por: Goetz, Benjamin, et al.
Publicado: (2016)

Mutant Cbl proteins as oncogenic drivers in myeloproliferative disorders
por: Naramura, Mayumi, et al.
Publicado: (2011)

A way to invade: A story of ErbB2 and lysosomes
por: Rafn, Bo, et al.
Publicado: (2012)

A monoclonal antibody targeting ErbB2 domain III inhibits ErbB2 signaling and suppresses the growth of ErbB2-overexpressing breast tumors
por: Meng, Y, et al.
Publicado: (2016)

Comparative oncology: ErbB-1 and ErbB-2 homologues in canine cancer are susceptible to cetuximab and trastuzumab targeting
por: Singer, Josef, et al.
Publicado: (2012)

Development of ErbB2-Targeting Liposomes for Enhancing Drug Delivery to ErbB2-Positive Breast Cancer
por: Ueno, Sho, et al.
Publicado: (2020)

The HSP90 inhibitor geldanamycin perturbs endosomal structure and drives recycling ErbB2 and transferrin to modified MVBs/lysosomal compartments
por: Cortese, Katia, et al.
Publicado: (2013)

Loss of Cbl and Cbl-b ubiquitin ligases abrogates hematopoietic stem cell quiescence and sensitizes leukemic disease to chemotherapy
por: An, Wei, et al.
Publicado: (2015)

Dual targeting of ErbB-2/ErbB-3 results in enhanced antitumor activity in preclinical models of pancreatic cancer
por: Ghasemi, R, et al.
Publicado: (2014)

Treatment of ErbB2 breast cancer by mitochondrial targeting
por: Eldad, Sophia, et al.
Publicado: (2020)

Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro
por: Robinson, M K, et al.
Publicado: (2008)

Targeting both Notch and ErbB-2 signalling pathways is required for prevention of ErbB-2-positive breast tumour recurrence
por: Pandya, K, et al.
Publicado: (2011)

Modulation of ErbB2 Blockade in ErbB2-Positive Cancers: The Role of ErbB2 Mutations and PHLDA1
por: Li, Guangyuan, et al.
Publicado: (2014)

Targeting of erbB3 receptor to overcome resistance in cancer treatment
por: Ma, Jian, et al.
Publicado: (2014)

ErbB polymorphisms: insights and implications for response to targeted cancer therapeutics
por: Alaoui-Jamali, Moulay A., et al.
Publicado: (2015)

ErbB Proteins as Molecular Target of Dietary Phytochemicals in Malignant Diseases
por: Filippi, Alexandru, et al.
Publicado: (2017)

Valproic acid exhibits anti-tumor activity selectively against EGFR/ErbB2/ErbB3-coexpressing pancreatic cancer via induction of ErbB family members-targeting microRNAs
por: Lin, Tingting, et al.
Publicado: (2019)

Endocrine resistance in breast cancer: new roles for ErbB3 and ErbB4
por: Sutherland, Robert L
Publicado: (2011)

Mutational Screening in Tyrosine-Kinase Domain of erbB1 And erbB2 Genes
por: ALONSO, Juan Manuel Fernández
Publicado: (2005)

ErbB activation signatures as potential biomarkers for anti-ErbB3 treatment in HNSCC
por: Alvarado, Diego, et al.
Publicado: (2017)

Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer
por: Wang, Shuiliang, et al.
Publicado: (2013)

Proliferation of Colorectal Cancer Is Promoted by Two Signaling Transduction Expression Patterns: ErbB2/ErbB3/AKT and MET/ErbB3/MAPK
por: Yao, Yong-Liang, et al.
Publicado: (2013)

Targeting inhibitor of apoptosis proteins in combination with ErbB antagonists in breast cancer
por: Foster, Fiona M, et al.
Publicado: (2009)

Theranostic Protein Targeting ErbB2 for Bioluminescence Imaging and Therapy for Cancer
por: Han, Xiao-Jian, et al.
Publicado: (2013)

SUN-442 EGFR/ErbB2 Targeted Therapy for Aggressive Prolactinomas
por: Cooper, Odelia, et al.
Publicado: (2019)

erbB in NSCLC as a molecular target: current evidences and future directions
por: Del Re, Marzia, et al.
Publicado: (2020)

Targeting ErbB3 Receptor in Cancer with Inhibitory Antibodies from Llama
por: Eliseev, Igor E., et al.
Publicado: (2021)

Nucleolar localization of the ErbB3 receptor as a new target in glioblastoma
por: Tagliaferro, Marzia, et al.
Publicado: (2022)

Design and selection of optimal ErbB-targeting bispecific antibodies in pancreatic cancer
por: Rabia, Emilia, et al.
Publicado: (2023)

Enhancement of in vivo targeting properties of ErbB2 aptamer by chemical modification
por: Park, Jun Young, et al.
Publicado: (2023)

EHD2 overexpression promotes tumorigenesis and metastasis in triple-negative breast cancer by regulating store-operated calcium entry
por: Luan, Haitao, et al.
Publicado: (2023)

Expression of oncogenes in thyroid tumours: coexpression of c-erbB2/neu and c-erbB.
por: Aasland, R., et al.
Publicado: (1988)

Nucleolin and ErbB2 inhibition reduces tumorigenicity of ErbB2-positive breast cancer
por: Wolfson, Eya, et al.
Publicado: (2018)

Nucleolin-binding by ErbB2 enhances tumorigenicity of ErbB2-positive breast cancer
por: Wolfson, Eya, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_4qoc3v3q9b64rua292dpc0q9s4